A new trading day began on Friday, with Medtronic Plc (NYSE: MDT) stock price down -2.26% from the previous day of trading, before settling in for the closing price of $99.0. MDT’s price has ranged from $79.55 to $106.33 over the past 52 weeks.
Healthcare Sector giant saw their annual sales surged by 0.39% over the last five years. Meanwhile, its annual earnings per share averaged 2.78%. With a float of $1.28 billion, this company’s outstanding shares have now reached $1.28 billion.
Medtronic Plc (MDT) Insider Activity
As we move forward, let’s examine how large-scale investors are investing in this stock of the Medical Devices Industry. The insider ownership of Medtronic Plc is 0.08%, while institutional ownership is 88.55%. The most recent insider transaction that took place on Nov 19 ’25, was worth 3,058,451. In this transaction EVP Global Ops & Supply Chain of this company sold 30,000 shares at a rate of $101.95, taking the stock ownership to the 46,016 shares. Before that another transaction happened on Nov 19 ’25, when Company’s Officer proposed sale 30,000 for $101.95, making the entire transaction worth $3,058,452.
Medtronic Plc (MDT) Earnings and Forecasts
In its latest quarterly report, released on 1/31/2025, the company reported earnings of 1.39 per share, which was $0.1 higher than the consensus estimate of $0.26. In terms of return on equity, this company recorded -19.55% in contrast with 50.0% return on Investment (trailing twelve months). Wall Street market experts anticipate that the next fiscal year will bring earnings of 1.69 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 2.78% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 6.20% during the next five years compared to 0.39% growth over the previous five years of trading.
Medtronic Plc (NYSE: MDT) Trading Performance Indicators
Here are Medtronic Plc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 1.80. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 3.57. Likewise, its price to free cash flow for the trailing twelve months is 23.83.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is 3.70, a number that is poised to hit 1.34 in the next quarter and is forecasted to reach 6.12 in one year’s time.
